The Weill Cornell Medicine (WCM) SPORE consists of four Projects focused on highly translational areas relevant to the detection and treatment of aggressive prostate cancer (PCa).
Projects 1, 2, and 4 build on first-in-class discoveries made by study co-leaders that are fostered with significant preliminary data. Project 3 builds on highly collaborative interactions with multiple SPORE groups, using state-of-the-art genomics in a Clinical Laboratory Improvement Amendments (CLIA) setting.
- Develop accurate biomarkers to assess the risk of PCa disease progression
- Develop new therapeutic approaches for clinically localized and CRPC that are hypothesis-driven
- Leverage existing and expand new infrastructure for the successful translation of pre-clinical studies into the clinic
- Train the next generation of PCa investigators through the CEP and DRP